• Bio-Techne reported fiscal Q3 revenue fell 2% to USD 311.4 million.
• GAAP EPS rose to USD 0.32, while adjusted EPS slipped to USD 0.53.
• GAAP operating income climbed 95% to USD 75.5 million as operating margin widened 12 percentage points to 24.2%.
• Protein Sciences revenue edged down 1% to USD 226.2 million, while Diagnostics and Spatial Biology revenue dropped 4% to USD 85.6 million.
• Kim Kelderman said large pharma delivered a sixth straight quarter of double-digit growth, while emerging biotech spending lagged and U.S. academic demand stabilized with low-single-digit growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605060630PR_NEWS_USPR_____CG52075) on May 06, 2026, and is solely responsible for the information contained therein.